Eli Lilly | LLY - Loan Capital

Stock Price
929.56
Daily Change
2.50 0.27%
Monthly
-7.82%
Yearly
28.00%
Q2 Forecast
907.42

Eli Lilly reported $40.87B in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Abbott USD 9.9B 1.7B Dec/2025
ALKERMES USD 285.82M 639K Sep/2024
Amgen USD 50B 2.43B Dec/2025
AstraZeneca USD 26.14B 19.58B Dec/2025
Baxter International USD 9.47B 726M Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Coherus Biosciences USD 51.08M 496K Dec/2025
Drreddys Laboratories INR 129.19M 1.84M Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Glaxosmithkline GBP 19.82B 203.13M Dec/2025
J&J USD 39.44B 30M Dec/2025
Medtronic USD 27.88B 255M Dec/2025
Merck USD 39.97B 6B Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 29.59B 5.35B Dec/2025
Novartis USD 29.59B 5.35B Dec/2025
Novo Nordisk DKK 118.94B 29.76B Dec/2025
Perrigo USD 3.6B 4.5M Dec/2025
Pfizer USD 57.41B 93M Sep/2025
Phibro Animal Health USD 603.6M 5.92M Dec/2025
Prestige Brands USD 1.05B 39.73M Dec/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 15.72B 2.45B Dec/2025
Sanofi EUR 15.72B 150.06M Dec/2025
United Therapeutics USD 100M 100M Jun/2024
Zoetis USD 9.04B 1.97B Dec/2025